All News
Opening Day Report
The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford).
Read Article
Treat-to-Target Works in Gout With No Cardiac Toxicity
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that allopurinol and febuxostat may effectively lower urate levels when used in a treat-to-target approach. Importantly, both urate-lowering therapies were very effective with 90% of patients reaching target urate levels. Additionally, both appeared safe, with no evidence of increased cardiovascular toxicity (Abstract #1900).
Read Article
NOR-DRUM Study: TNF Inhibitor Therapeutic Drug Monitoring is Effective
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that proactive therapeutic drug monitoring, a newer treatment strategy where a patient’s drug serum levels are regularly assessed to adjust the dose and intervals, controlled disease more effectively than standard therapy with infliximab, a tumor necrosis factor (TNF) inhibitor.
Read Article
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Links:
Eric Dein ericdeinmd ( View Tweet)
Links:
Pedro Castillo _Castillo_Pedro ( View Tweet)
Links:
Links:
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Dr. Antoni Chan synovialjoints ( View Tweet)
